NR1H4 and metabolic dysfunction-associated steatohepatitis: Moreover, OCA, a farnesoid X-receptor (FXR) agonist finished with Phase III clinical trials was administered to DIO-CCl4 mice, and correlation analysis among metabolites and the OCA-mediated amelioration in NASH marker was performed.